ZURA
Zura Bio Ltd
Next earnings Aug 12, 2026 · consensus $-0.19 EPS
Last earnings -7.2% on 2026-05-07
$5.35
▲ +17.84%$5.35▲ +409.52%
over 1Y
L $1.05EODHDH $7.00
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+17.8%
1W+17.8%
1M+24.1%
3M-9.8%
YTD-3.6%
1Y+409.5%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 14 analysts
Strong Buy
Conservative balance sheet (liabilities/equity 0.12x).
Return on equity -67.6% · latest
Zura Bio Ltd shows limited reported revenue, and -67.6% ROE.
Financials · annual, by fiscal year
| Line item | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$27.2M | -$62.6M | -$55.2M | -$75.2M |
| Net income | -$25.7M | -$60.4M | -$52.4M | -$68.7M |
| Diluted EPS | -$141.97 | -$2.09 | -$0.60 | -$1.06 |
| Net margin | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$398M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-13.5%
FCF yield-12.8%
Quality & risk
ROIC (est.)-58.5%
Free cash flow-$64.9M
Total debt—
Net cash$109M
Piotroski F-Score1/6
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+38.8%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
- 8-K Officer / director change2026-06-18
- 8-K Officer / director change2026-05-22
- 8-K Earnings results2026-05-07
- 10-Q Quarterly report2026-05-07
- DEF 14A Proxy statement2026-04-30
- 8-K Officer / director change2026-04-23
- 8-K Earnings results2026-03-19
- 10-K Annual report2026-03-19
- 8-K Reg FD disclosure2026-03-10
Recent filings
all on EDGAR ↗3Period ending 2026-04-172026-06-22open ↗4Period ending 2026-06-172026-06-22open ↗4Period ending 2026-06-172026-06-22open ↗4Period ending 2026-06-172026-06-22open ↗4Period ending 2026-06-172026-06-22open ↗4Period ending 2026-06-172026-06-22open ↗4Period ending 2026-06-172026-06-22open ↗4Period ending 2026-06-172026-06-22open ↗8-KPeriod ending 2026-06-172026-06-18open ↗DEFA14AFiling2026-05-22open ↗8-KPeriod ending 2026-05-202026-05-22open ↗SCHEDULE 13G/AFiling2026-05-15open ↗
Frequently asked
- Is Zura Bio Ltd (ZURA) a buy?
- ZURA currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.12x).
- What is Zura Bio Ltd's quality score?
- ZURA scores 36.179487179487175/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001855644, latest 10-Q filed 2026-05-07) · EODHD · as of 6/26/2026, 6:13:06 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.